New biomarker discovered for asymptomatic stages of Alzheimer’s disease
A novel biomarker, miR-519a-3p, has been identified by researchers as a potential tool for early diagnosis and treatment of neurodegenerative diseases, particularly Alzheimer’s disease (AD) in its asymptomatic stages. The discovery was made by the Molecular and Cellular Neurobiotechnology group at the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona.
miR-519a-3p, a microRNA, is directly associated with the expression of the cellular prion protein (PrPC), which is known to be deregulated in individuals with neurodegenerative conditions like AD. Detecting AD in its early stages is crucial for effective treatment, and stable biomarkers such as microRNAs could play a significant role in this process. While microRNA dysregulation is observed in AD patients, this study is the first to specifically link miR-519a-3p to the decrease in PrPC production during disease progression.
Dr José Antonio del Río, co-leader of the study and IBEC principal investigator, highlighted the importance of early diagnosis, stating, “Currently, tests for diagnosing Alzheimer’s disease are typically conducted after symptoms appear, leading to underlying cognitive impairment. The identification of this microRNA could potentially enhance diagnostic accuracy in the early stages of the disease.”
The study also examined the presence of the biomarker in samples from other neurodegenerative diseases, shedding light on its potential broader applications.
Join the webinar on Neurological disorders
Discover more about the role of organoids in advancing the treatment of neurological disorders by participating in our upcoming webinar. Organoids, which are miniature 3D models of human organs, are revolutionizing neuroscience research by providing insights into the complexities of the human brain. Esteemed experts will discuss the latest advancements in organoid technology and its implications for early drug discovery in neurological conditions.
